Naringin used in preparing medicine for curing acute and chronic bronchitis

A technology of bronchitis and naringin, which is applied in the field of naringin for the preparation of medicines for treating acute and chronic bronchitis, can solve the problems of acute and chronic bronchitis that have not been reported, and achieve good cough-relieving effect and rapid curative effect , the effect of stable quality

Inactive Publication Date: 2003-07-23
广东伯克生物医药有限公司
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the application of nari

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The percentages of solids in solid mixtures, liquids in liquids, and solids in liquids in each example are calculated in wt / wt, vol / vol, wt / vol, respectively, unless otherwise specified. Example 1. Antitussive pharmacological experiment of naringin drug

[0019] 1. Experimental animals: NIH mice, male, weighing 18.2-21.7g, normal-grade standard, 60 in total. Animals were first weighed, numbered, and a total of 45 healthy mice with a body weight of 18.5-21.0 g were selected. Sorted according to body weight, divided into three groups by random grouping method, 15 in each group. A negative control group, a positive control group and a naringin drug sample group were set up.

[0020] 2. Sample source and processing:

[0021] 1) Blank control group: physiological saline, NaCl content 0.9%.

[0022] 2) Positive control group: two tablets of methorphan were dissolved in 20 ml of normal saline to obtain a positive control methorphan solution, the concentration of methorphan...

Embodiment 2

[0036] From the comparison of the tolerance time of the naringin sample and the positive control drug methorphan, oral administration to stimulate mice to cause cough, naringin has a significant prolongation of the tolerance time of the mice, which is higher than that of the positive control drug methorphan. There is a statistically significant difference over a long period of time. It shows that the tolerance time of naringin to the cough caused by stimulating mice is longer than that of methorphan, and the curative effect is significant. It has a good therapeutic effect on acute and chronic bronchitis, and has a good effect on relieving cough. Example 2. Toxicological experiments of naringin drugs

[0037] Under the temperature of 24±1° C. and the humidity of 65±5%, 20 healthy clean-grade NIH mice aged 7-8 weeks were selected, half male and half female, weighing 20-22 g. The feed and water were disinfected, and the animals were raised under normal feed conditions before th...

Embodiment 3

[0039] On the 10th day, all mice survived, and no toxic reaction was seen with naringin at a dose of 900 mg / kg. The pathological examination of each organ of the mice was normal, no pathological changes were found, and the weight of the mice did not lose weight within 10 days. Therefore, it shows that the naringin drug of the present invention has no toxicity when it is orally administered to animals. Example 3. Naringin capsule preparation

[0040] Prepare gelatin capsules according to the following ingredient proportions:

[0041] Naringin 100

[0042] dry starch 40

[0043]Micronized silica gel 10

[0044] Mix the auxiliary materials and naringin evenly, put them into transparent capsules, and get ready. Capacity: 150mg / capsule. Example 4. Naringin Tablets

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A medicine for treating acute and chronic bronchitis features that its active component is naringoside. Its advantages are high curative effect and no toxic by-effect.

Description

technical field [0001] The invention relates to the application of naringin in preparing medicine for treating acute and chronic bronchitis and cough with excessive phlegm. Background technique [0002] Acute and chronic bronchitis are acute and chronic non-specific inflammation of the trachea, bronchial mucosa and surrounding tissues caused by infection or non-infection factors. Clinically, it is characterized by cough and expectoration accompanied by wheezing and recurrent attacks. It belongs to the category of cough, phlegm retention and asthma in traditional Chinese medicine. It is a common and frequently-occurring disease. [0003] For treating acute and chronic bronchitis with traditional Chinese medicine, people have carried out a lot of efforts, such as Juhongli paste, Keke tablets, etc., have entered the market. But in terms of its characteristics, the currently marketed drugs also have the disadvantage of large doses and inconvenience...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P11/00A61P11/10A61P11/14
Inventor 苏薇薇王永刚方铁铮彭维吴忠
Owner 广东伯克生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap